Cargando…
Paritaprevir ameliorates experimental acute lung injury in vitro and in vivo
Paritaprevir is a potent inhibitor of the NS3/4A protease used to treat chronic hepatitis C virus infection. However, its therapeutic effect on acute lung injury (ALI) remains to be elucidated. In this study, we investigated the effect of paritaprevir on a lipopolysaccharide (LPS)-induced two-hit ra...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Pharmaceutical Society of Korea
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258477/ https://www.ncbi.nlm.nih.gov/pubmed/37306915 http://dx.doi.org/10.1007/s12272-023-01451-4 |